Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Cagrilintide/semaglutide

A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight

Novo Nordisk · Phase 3 · Withdrawn · Enrollment 0

NCT07357766

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
CagriSema B in device 2 + Placebo in device 1n/rn/rn/rn/r
CagriSema in device 1 + Placebo in device 2n/rn/rn/rn/r
Placebo in device 1 + Placebo in device 2n/rn/rn/rn/r

Not shown

  • CagriSema B in device 2 + Placebo in device 1: endpoint not reported
  • CagriSema in device 1 + Placebo in device 2: endpoint not reported
  • Placebo in device 1 + Placebo in device 2: endpoint not reported